What is your company’s biggest achievement in the last year?Following years of research and development and a $2.2 million investment, PXi introduced the X-RAD SmART in 2015. This is the industry’s most advanced image-guided radiation therapy system. With several new sales and X-RAD SmART system installations worldwide, Precision X-ray has grown significantly and profitably in […]
Get Instant Access to This Article
Subscribe to Hartford Business Journal and get immediate access to all of our subscriber-only content and much more.
- Critical Hartford and Connecticut business news updated daily.
- Immediate access to all subscriber-only content on our website.
- Bi-weekly print or digital editions of our award-winning publication.
- Special bonus issues like the Hartford Book of Lists.
- Exclusive ticket prize draws for our in-person events.
Click here to purchase a paywall bypass link for this article.
What is your company's biggest achievement in the last year?
Following years of research and development and a $2.2 million investment, PXi introduced the X-RAD SmART in 2015. This is the industry's most advanced image-guided radiation therapy system. With several new sales and X-RAD SmART system installations worldwide, Precision X-ray has grown significantly and profitably in 2015.
How do you plan to keep your business going even after your current top executive retires?
PXi President and part owner Bill McLaughlin will continue to lead the company following Brian Dermott's retirement.
Who is most responsible for your company's success today?
Since the company's inception, Brian Dermott has never been content in staying the course. Through Dermott's leadership and financial backing, PXi has emerged as the leading provider of safe, high-output X-Ray irradiators used in modern translational research. While Dermott has pushed the company's engineers and research partners to develop new technology and better systems, he credits current President Bill McLaughlin and the entire PXi team for developing high-precision systems that open up new applications in oncology, radiobiology and immunology.Â